The company says the early trial of its hair-loss therapy saw patients benefit from six times more hair growth than placebo.
ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.
Ryght AI has announced a strategic collaboration with QPS Holdings for optimising clinical trial processes globally.
RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback